Germline variation in RASAL2 may predict survival in patients with RAS-activated colorectal cancer.

Although there was a trend for a predictive effect on RAS compared with RAF mutant backgrounds, this did not reach statistical significance (for KRAS versus BRAF mutant, p Z ‐test = 0.097, NRAS versus BRAF mutant, p Z ‐test = 4.6 × 10 −2 , combined RAS versus BRAF mutant, p Z ‐test = 8.5 × 10 −2 ).

also in 111,027 other papers